- Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;
- 86.3% DCR, with durable responses observed in heavily pretreated patients
SAN DIEGO, CA - November 17, 2026/PRNewswire — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced updated clinical data from the Phase 1/2 expansion study evaluating ozekibart (INBRX-109), an investigational tetravalent death receptor 5 (DR5) agonist, in combination with irinotecan and temozolomide (IRI/TMZ) in patients with relapsed or refractory Ewing sarcoma. The data will be presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting.
“The updated clinical data to be presented at CTOS underscore the deep activity and expanding reach of ozekibart in aggressive, difficult-to-treat bone and soft tissue sarcomas,” said Mark Lappe, Chief Executive Officer of Inhibrx.